Series D Surge: Star Therapeutics $125M Sales Trigger
Star Therapeutics just closed $125M Series D. Your signal to drive antibody R&D workflows. Connect with CEO Adam Rosenthal. Pitch integrated LIMS and AI analytics. Fuel your pipeline and hit quota.
Published on
Do not index
Do not index
🚀 Battle Card: Star Therapeutics
Quick trigger:
👤 Decision Maker in the News
- Adam Rosenthal, Ph.D., Founder & CEO 📧 <adam@star-therapeutics.com>
💡 Why It Matters
- Oversubscribed Series D funding signals strong investor confidence in antibody platforms, making this Star Therapeutics sales trigger your opener for R&D scale conversations. → [Source](https://vcnewsdaily.com/star-therapeutics/venture-capital-funding/lzfxwpyvjx)
🎯 Core Pain Point
- Streamlining antibody R&D workflows
- Scaling data analysis for clinical-stage development
💰 What to Pitch
- Primary: Integrated Lab Information Management System → Accelerate candidate discovery cycles
- Expansion: AI-driven Biostatistics Analytics → Enhance trial insights and decision speed
🗺️ Quick Context
- HQ: South San Francisco, CA
- Employees: ≈ 150
- Rev: ≈ $20 M
🤼 Competitive Intel
Which other vendors you’ll probably face to win Star Therapeutics’s business.
- GenScript — Discovery platforms
- Unique edge: End-to-end antibody engineering
- Evaluated by Dir. R&D for candidate generation
- WuXi Biologics — CDMO services
- Unique edge: Large-scale biologics manufacturing
- Evaluated by VP Ops for scale-up flexibility
- Benchling — LIMS & bioinformatics
- Unique edge: Collaborative R&D notebook and data management
- Evaluated by CSO for data reporting
- LabVantage — LIMS
- Unique edge: Comprehensive lab management
- Evaluated by Lab Manager for compliance
- Veeva Systems — Clinical data management
- Unique edge: Cloud-based CTMS & eTMF
- Evaluated by Clinical Ops for trial oversight
✅ Do-Now Checklist
Connect with Adam Rosenthal via email (see above)
Generate email + DM with the Copy-My-Prompt block referencing the Star Therapeutics sales trigger and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Capitalize on this Star Therapeutics sales trigger now—never miss a beat.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑Integrated LIMS to accelerate candidate discovery cycles❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Adam
COMPANY = Star Therapeutics
DEPT = R&D
SIZE = 150
BOTTLENECK = data analysis bottlenecks for clinical development
EVENT = raises $125M Series D
DETAIL = oversubscribed Series D financing
PAIN = streamlining antibody R&D workflows
SRC = https://vcnewsdaily.com/star-therapeutics/venture-capital-funding/lzfxwpyvjx
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ 150
REV_EST = ≈ $20 M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 150-person R&D
Adam—noticed your R&D team is ≈ 150.
That’s when data analysis bottlenecks for clinical development slows growth.
We helped ≈ TBD fix this with Integrated LIMS to accelerate candidate discovery cycles.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about oversubscribed Series D financing — streamlining antibody R&D workflows.
Integrated LIMS to accelerate candidate discovery cycles. ≈ TBD.
Quick chat?